Última atualização: Agosto 17, 2026
Célula-tronco mesenquimal (MSC) transplantation is a novel treatment for liver diseases due to the roles of MSCs in regeneration, fibrosis inhibition and immune regulation. No entanto, the mechanisms are still not completely understood. Despite the significant efficacy of MSC therapy in animal models and preliminary clinical trials, issues remain. The efficacy and safety of MSC-based therapy in the treatment of liver diseases remains a challenging issue that requires more investigation. This article reviews recent studies on the mechanisms of MSCs in liver diseases and the associated challenges and suggests potential future applications.
Introdução
After Friedenstein et al. (1) first isolated and identified stromal cells from bone marrow in 1966, células-tronco mesenquimais (MSC) were isolated from various tissues, como o cordão umbilical (2, 3), placenta (4), tecido adiposo (5, 6), líquido amniótico (7, 8), menstrual blood (9, 10), e polpa dentária (11). The immunomodulatory properties, limited self-renewal capacity, and multi-lineage development of MSCs make these cells ideal candidates for clinical applications in different diseases (12). The low inherent immunogenicity of MSCs guarantees transplant safety (13). Even HLA-mismatched MSCs could be used for many clinical applications, especially for stem cell-based therapies (14). Além disso, the ability of these cells to home to specific organs and lesions is the key to the curative effect of MSC transplantation (13). MSC surface chemokine receptors, such as CCR1, CCR4, CCR7, CXCR5, and CCR10, are involved in the migration of MSCs into injured tissues along chemokine gradients (15). MSCs are administered to patients by various routes, such as intravascular injection and local transplantation, to alleviate diseases (16–18).
Liver diseases are a global health issue that cause a large number of deaths every year (19, 20). Transplante de fígado, which is recommended as the only effective treatment method available for advanced liver diseases, is limited by high costs and a shortage of donor livers (21). MSC transplantation brings new hope to the treatment of liver diseases. Despite their different etiologies, symptoms and physiological processes, multiple kinds of life-threating liver diseases can be effectively treated by cell-based therapy, as three decades of clinical and preclinical studies proved. Among the most used source of cells for allogenic/autologous transplantation, the two most largely clinically infused cells are undoubtedly primary hepatocyte and MSCs. MSCs have been administered in hundreds of clinical trials during the past decades, and for a plethora of indications (Mesa 1). Although many laboratory and clinical trials have confirmed the efficacy of MSCs in a variety of diseases, there are still no guidelines to regulate MSC clinical applications (29–31).
Revisão de Caso Científico
Você gostaria de entender se os programas clínicos atuais, desenvolvimentos de pesquisa recentes, ou abordagens emergentes podem ser relevante para sua situação individual?
Compartilhe sua dúvida com nossa equipe de pesquisa científica e receba informações focadas nas áreas de pesquisa atual que podem ser relevante para o seu caso.
- Revisão das informações que você fornece
- Informações relevantes sobre pesquisas e programas clínicos
- Uma resposta clara focada na sua situação
Sem obrigação. Sua pergunta será analisada confidencialmente.
Apenas informações educacionais e de pesquisa. Este serviço não constituem aconselhamento médico, diagnóstico, prescrição, ou um personalizado recomendação de tratamento.
